Potential treatment targets in IPF include the MUC5B promoter or telomere gene variants, which are appealing due to the elevated expression of MUC5B (173) and shortened telomeres (233–236) in all individuals with IPF, regardless of a genetic mutation. The gene discussed is MUC5B; the disease is idiopathic pulmonary fibrosis.